ITULAZAX Post Authorization Safety (IPAS) Study: A prospective, non-interventional study assessing the safety and tolerability of ITULAZAX in adults with tree pollen allergy in real-life practice (IPAS Study)

First published 19/09/2019

Last updated 22/02/2024

EU PAS number:

EUPAS31470

Study

Finalised

Documents

Study protocol

Initial protocol

190910-NIS-PASS-ITULAZAX Final Protocol version 1.0

English (262.52 KB - PDF) View document

Updated protocol

20220811-NIS-PASS-ITULAZAX Final Protocol version 4.0_04102022_update sponsor address

First published: 22/02/2024

English (426.86 KB - PDF) View document

Study results

2023-06-09_NI-TT-01_Overall Study Report ITULAZAX_Synopsis_Final version

English (223.86 KB - PDF) View document

Study report

Other information

Secondary tabs